ALCAR Exerts Neuroprotective and Pro-Neurogenic Effects by Inhibition of Glial Activation and Oxidative Stress via Activation of the Wnt/β-Catenin Signaling in Parkinsonian Rats

Molecular Neurobiology

Volumn 53, Issue 7, 2016, Pages 4286-4301

  Singh, Sonu ^a   Mishra, Akanksha ^a   Shukla, Shubha ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Acetyl l carnitine (ALCAR); Neural stem cells; Neuroblasts; Neuroprotection; Oxidative stress; Wnt catenin pathway

Indexed keywords

BETA CATENIN; GLYCOGEN SYNTHASE KINASE 3BETA; LEVACECARNINE; OXIDOPAMINE; WNT PROTEIN; ACETYLCARNITINE; ANTIOXIDANT; NEUROPROTECTIVE AGENT; NITRITE; REACTIVE OXYGEN METABOLITE;

ADRENERGIC NERVE; ADULT; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BETA CATENIN SIGNALING PATHWAY; BRAIN REGION; CELL ACTIVATION; CELL POPULATION; CELL SURVIVAL; CIRCLING BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; DRUG MECHANISM; ENZYME ACTIVATION; GLIA CELL; INHIBITION KINETICS; LIPID PEROXIDATION; MALE; MOTOR COORDINATION; NERVE CELL NECROSIS; NEURAL STEM CELL; NEUROBLAST; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PHENOTYPE; PROTEIN LOCALIZATION; PROTEIN STABILITY; RAT; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA PARS COMPACTA; WNT SIGNALING PATHWAY; ANIMAL; ATAXIA; AXON; BRAIN; CELL NUCLEUS; COMPLICATION; DISEASE MODEL; DOPAMINERGIC NERVE CELL; DRUG EFFECTS; GLIA; METABOLISM; NERVOUS SYSTEM DEVELOPMENT; PATHOLOGY; PHOSPHORYLATION; SPRAGUE DAWLEY RAT; WNT SIGNALING;

ACETYLCARNITINE; ANIMALS; ANTIOXIDANTS; ATAXIA; AXONS; BEHAVIOR, ANIMAL; BRAIN; CELL NUCLEUS; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; GLYCOGEN SYNTHASE KINASE 3 BETA; LIPID PEROXIDATION; MALE; NEURAL STEM CELLS; NEUROGENESIS; NEUROGLIA; NEUROPROTECTIVE AGENTS; NITRITES; OXIDATIVE STRESS; OXIDOPAMINE; PARKINSON DISEASE; PHENOTYPE; PHOSPHORYLATION; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; WNT SIGNALING PATHWAY;

EID: 84938544529     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-015-9361-5     Document Type: Article

References (57)

1. Walsh S, Finn DP, Dowd E (2011) Time-course of nigrostriatal neurodegeneration and neuroinflammation in the 6-hydroxydopamine-induced axonal and terminal lesion models of Parkinson’s disease in the rat. Neuroscience 175:251–261
2. Block ML, Zecca L, Hong JS (2007) Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 8:57–69
3. Sawada H, Hishida R, Hirata Y, Ono K, Suzuki H, Muramatsu S et al (2007) Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine. J Neurosci Res 85:1752–1761
4. Hirsch EC, Hunot S (2009) Neuroinflammation in Parkinson’s disease: a target for neuroprotection? Lancet Neurol 8:382–397
5. Hu X, Zhang D, Pang H, Caudle WM, Li Y, Gao H et al (2008) Macrophage antigen complex-1 mediates reactive microgliosis and progressive dopaminergic neurodegeneration in the MPTP model of Parkinson’s disease. J Immunol 181:7194–7204
6. Morale MC et al (2006) Estrogen, neuroinflammation and neuroprotection in Parkinson’s disease: glia dictates resistance versus vulnerability to neurodegeneration. Neuroscience 138:869–878
7. Yang F, Liu Y, Tu J, Wan J, Zhang J, Wu B et al (2014) Activated astrocytes enhance the dopaminergic differentiation of stem cells and promote brain repair through bFGF. Nat Commun 5:5627
8. Monje ML, Toda H, Palmer TD (2003) Inflammatory blockade restores adult hippocampal neurogenesis. Science 302:1760–1765
9. Worlitzer MM, Bunk EC, Hemmer K, Schwamborn JC (2012) Anti-inflammatory treatment induced regenerative oligodendrogenesis in parkinsonian mice. Stem Cell Res Ther 3:33
10. Zhang L, Yang X, Yang S, Zhang J (2011) The Wnt/beta-catenin signaling pathway in the adult neurogenesis. Eur J Neurosci 33:1–8
11. L’Episcopo F, Serapide MF, Tirolo C, Testa N, Caniglia S, Morale MC et al (2011) A Wnt1 regulated Frizzled-1/beta-Catenin signaling pathway as a candidate regulatory circuit controlling mesencephalic dopaminergic neuron-astrocyte crosstalk: therapeutical relevance for neuron survival and neuroprotection. Mol Neurodegener 6:49
12. Gordon MD, Nusse R (2006) Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem 281:22429–22433
13. L’Episcopo F, Tirolo C, Testa N, Caniglia S, Morale MC, Deleidi M et al (2012) Plasticity of subventricular zone neuroprogenitors in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse model of Parkinson’s disease involves cross talk between inflammatory and Wnt/beta-catenin signaling pathways: functional consequences for neuroprotection and repair. J Neurosci 32:2062–2085
14. Dun Y, Li G, Yang Y, Xiong Z, Feng M, Wang M et al (2012) Inhibition of the canonical Wnt pathway by Dickkopf-1 contributes to the neurodegeneration in 6-OHDA-lesioned rats. Neurosci Lett 525:83–88
15. Savitha S, Tamilselvan J, Anusuyadevi M, Panneerselvam C (2005) Oxidative stress on mitochondrial antioxidant defense system in the aging process: role of DL-alpha-lipoic acid and L-carnitine. Clin Chim Acta 355:173–180
16. Harsing LG Jr, Sershen H, Toth E, Hashim A, Ramacci MT, Lajtha A (1992) Acetyl-L-carnitine releases dopamine in rat corpus striatum: an in vivo microdialysis study. Eur J Pharmacol 218:117–121
17. Tolu P, Masi F, Leggio B, Scheggi S, Tagliamonte A, De Montis MG et al (2002) Effects of long-term acetyl-L-carnitine administration in rats: I. increased dopamine output in mesocorticolimbic areas and protection toward acute stress exposure. Neuropsychopharmacology 27:410–420
18. Zaitone SA, Abo-Elmatty DM, Shaalan AA (2011) Acetyl-L-carnitine and alpha-lipoic acid affect rotenone-induced damage in nigral dopaminergic neurons of rat brain, implication for Parkinson’s disease therapy. Pharmacol Biochem Behav 100:347–360
19. Hota KB, Hota SK, Chaurasia OP, Singh SB (2012) Acetyl-L-carnitine-mediated neuroprotection during hypoxia is attributed to ERK1/2-Nrf2-regulated mitochondrial biosynthesis. Hippocampus 22:723–736
20. Montgomery SA, Thal LJ, Amrein R (2003) Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer’s disease. Int Clin Psychopharmacol 18:61–71
21. Shukla S, Chaturvedi RK, Seth K, Roy NS, Agrawal AK (2009) Enhanced survival and function of neural stem cells-derived dopaminergic neurons under influence of olfactory ensheathing cells in parkinsonian rats. J Neurochem 109:436–451
22. Nasca C, Xenos D, Barone Y, Caruso A, Scaccianoce S, Matrisciano F et al (2013) l-acetylcarnitine causes rapid antidepressant effects through the epigenetic induction of mGlu2 receptors. Proc Natl Acad Sci U S A 110(12):4804–4809
23. Rozas G, Guerra MJ, Labandeira-Garcia JL (1997) An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism. Brain Res Brain Res Protoc 2:75–84
24. Espejo EF, Montoro RJ, Armengol JA, López-Barneo J (1998) Cellular and functional recovery of Parkinsonian rats after intrastriatal transplantation of carotid body cell aggregates. Neuron 20:197–206
25. Colado MI, O'Shea E, Granados R, Misra A, Murray TK, Green AR (1997) A study of the neurotoxic effect of MDMA (‘ecstasy’) on 5-HT neurones in the brains of mothers and neonates following administration of the drug during pregnancy. Br J Pharmacol 121:827–833
26. Ellman GL (1959) Tissue sulfhydryl groups. Arch Biochem Biophys 82:70–77
27. Raghavendra V, Kulkarni SK (2000) Melatonin reversal of DOI-induced hypophagia in rats; possible mechanism by suppressing 5-HT(2A) receptor-mediated activation of HPA axis. Brain Res 860:112–118
28. van den Munckhof P, Luk KC, Ste-Marie L, Montgomery J, Blanchet PJ, Sadikot AF et al (2003) Pitx3 is required for motor activity and for survival of a subset of midbrain dopaminergic neurons. Development 130:2535–2542
29. Castelo-Branco G, Rawal N, Arenas E (2004) GSK-3beta inhibition/beta-catenin stabilization in ventral midbrain precursors increases differentiation into dopamine neurons. J Cell Sci 117:5731–5737
30. Kuruvilla KP, Nandhu MS, Paul J, Paulose CS (2013) Oxidative stress mediated neuronal damage in the corpus striatum of 6-hydroxydopamine lesioned Parkinson’s rats: neuroprotection by serotonin, GABA and bone marrow cells supplementation. J Neurol Sci 331:31–37
31. Rani PJ, Panneerselvam C (2002) Effect of L-carnitine on brain lipid peroxidation and antioxidant enzymes in old rats. J Gerontol A Biol Sci Med Sci 57:B134–B137
32. Hagen TM, Liu J, Lykkesfeldt J, Wehr CM, Ingersoll RT, Vinarsky V et al (2002) Feeding acetyl-L-carnitine and lipoic acid to old rats significantly improves metabolic function while decreasing oxidative stress. Proc Natl Acad Sci U S A 99:1870–1875
33. Zhang H, Jia H, Liu J, Ao N, Yan B, Shen W et al (2010) Combined R-alpha-lipoic acid and acetyl-L-carnitine exerts efficient preventative effects in a cellular model of Parkinson’s disease. J Cell Mol Med 14:215–225
34. Truong L, Allbutt H, Kassiou M, Henderson JM (2006) Developing a preclinical model of Parkinson’s disease: a study of behaviour in rats with graded 6-OHDA lesions. Behav Brain Res 169:1–9
35. Jones GH, Robbins TW (1992) Differential effects of mesocortical, mesolimbic, and mesostriatal dopamine depletion on spontaneous, conditioned, and drug-induced locomotor activity. Pharmacol Biochem Behav 43:887–895
36. Hauber W (1998) Involvement of basal ganglia transmitter systems in movement initiation. Prog Neurobiol 56:507–540
37. Grealish S, Mattsson B, Draxler P, Björklund A (2010) Characterisation of behavioural and neurodegenerative changes induced by intranigral 6-hydroxydopamine lesions in a mouse model of Parkinson’s disease. Eur J Neurosci 31:2266–2278
38. Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D (1999) Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 46:598–605
39. Marinova-Mutafchieva L, Sadeghian M, Broom L, Davis JB, Medhurst AD, Dexter DT (2009) Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6-hydroxydopamine model of Parkinson’s disease. J Neurochem 110:966–975
40. Halliday GM, Stevens CH (2011) Glia: initiators and progressors of pathology in Parkinson’s disease. Mov Disord 26:6–17
41. Yang YJ, Zhang S, Ding JH, Zhou F, Hu G (2009) Iptakalim protects against MPP+-induced degeneration of dopaminergic neurons in association with astrocyte activation. Int J Neuropsychopharmacol 12:317–327
42. Chung YC, Kim SR, Park JY, Chung ES, Park KW, Won SY et al (2011) Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation. Neuropharmacology 60:963–974
43. Altun Z, Olgun Y, Ercetin P, Aktas S, Kirkim G, Serbetcioglu B et al (2014) Protective effect of acetyl-l-carnitine against cisplatin ototoxicity: role of apoptosis-related genes and pro-inflammatory cytokines. Cell Prolif 47:72–80
44. Stott SR, Barker RA (2014) Time course of dopamine neuron loss and glial response in the 6-OHDA striatal mouse model of Parkinson’s disease. Eur J Neurosci 39:1042–1056
45. Andersson E, Tryggvason U, Deng Q, Friling S, Alekseenko Z, Robert B et al (2006) Identification of intrinsic determinants of midbrain dopamine neurons. Cell 124:393–405
46. Volpicelli F, De Gregorio R, Pulcrano S, Perrone-Capano C, di Porzio U, Bellenchi GC (2012) Direct regulation of Pitx3 expression by Nurr1 in culture and in developing mouse midbrain. PLoS ONE 7:e30661
47. Das S, Dutta K, Kumawat KL, Ghoshal A, Adhya D, Basu A (2011) Abrogated inflammatory response promotes neurogenesis in a murine model of Japanese encephalitis. PLoS ONE 6:e17225
48. Baker SA, Baker KA, Hagg T (2004) Dopaminergic nigrostriatal projections regulate neural precursor proliferation in the adult mouse subventricular zone. Eur J Neurosci 20:575–579
49. Park D, Xiang AP, Mao FF, Zhang L, Di CG, Liu XM et al (2010) Nestin is required for the proper self-renewal of neural stem cells. Stem Cells 28:2162–2171
50. Roybon L, Hjalt T, Stott S, Guillemot F, Li JY, Brundin P (2009) Neurogenin2 directs granule neuroblast production and amplification while NeuroD1 specifies neuronal fate during hippocampal neurogenesis. PLoS ONE 4:e4779
51. Gao Z, Ure K, Ables JL, Lagace DC, Nave KA, Goebbels S et al (2009) Neurod1 is essential for the survival and maturation of adult-born neurons. Nat Neurosci 12:1090–1092
52. Cuccurazzu B, Bortolotto V, Valente MM, Ubezio F, Koverech A, Canonico PL et al (2013) Upregulation of mGlu2 receptors via NF-kappaB p65 acetylation is involved in the proneurogenic and antidepressant effects of acetyl-L-carnitine. Neuropsychopharmacology 38:2220–2230
53. Chen G, Bower KA, Ma C, Fang S, Thiele CJ, Luo J (2004) Glycogen synthase kinase 3beta (GSK3beta) mediates 6-hydroxydopamine-induced neuronal death. Faseb J 18:1162–1164
54. Jiang X, Tian Q, Wang Y, Zhou XW, Xie JZ, Wang JZ et al (2011) Acetyl-L-carnitine ameliorates spatial memory deficits induced by inhibition of phosphoinositol-3 kinase and protein kinase C. J Neurochem 118:864–878
55. Kalani MY, Cheshier SH, Cord BJ, Bababeygy SR, Vogel H, Weissman IL et al (2008) Wnt-mediated self-renewal of neural stem/progenitor cells. Proc Natl Acad Sci U S A 105:16970–16975
56. Kunke D, Bryja V, Mygland L, Arenas E, Krauss S (2009) Inhibition of canonical Wnt signaling promotes gliogenesis in P0-NSCs. Biochem Biophys Res Commun 386:628–633
57. Galli S, Lopes DM, Ammari R, Kopra J, Millar SE, Gibb A et al (2014) Deficient Wnt signalling triggers striatal synaptic degeneration and impaired motor behaviour in adult mice. Nat Commun 5:4992